| |
ER/PR + HER2-
|
ER/PR + HER2+
|
HER2 type
|
Basal-like
|
Unclassified
|
|---|
|
n
|
OR
|
n
|
OR
|
n
|
OR
|
n
|
OR
|
n
|
OR
|
|---|
|
EGFR
|
|
Positive
|
16
|
1.0 (Ref)
|
5
|
2.77 (0.69, 9.44)
|
19
|
9.64 (3.76, 20.53)
|
34
|
104.55 (41.51, 856.77)
|
0
|
0.00 (0.00, 2.75)
|
|
Negative
|
283
| |
35
| |
39
| |
3
| |
28
| |
|
PTEN
|
|
Reduced
|
156
|
1.0 (Ref)
|
18
|
0.75 (0.35, 1.55)
|
16
|
0.31(0.16, 0.63)
|
28
|
2.57 (1.11, 6.37)
|
16
|
1.31 (0.55, 3.15)
|
|
Normal
|
140
| |
23
| |
42
| |
9
| |
12
| |
|
Bcl-
2
|
|
Positive
|
249
|
1.0 (Ref)
|
27
|
0.41 (0.19, 0.99)
|
7
|
0.02 (0.01, 0.07)
|
6
|
0.04 (0.01, 0.12)
|
14
|
0.20 (0.08, 0.49)
|
|
Negative
|
51
| |
13
| |
51
| |
31
| |
14
| |
|
c
-Kit
|
|
Positive
|
15
|
1.0 (Ref)
|
0
|
0.00 (0.00, 2.16)
|
7
|
2.70 (0.84, 7.48)
|
10
|
7.50 (2.60, 20.96)
|
1
|
0.73 (0.02, 5.29)
|
|
Negative
|
287
| |
41
| |
51
| |
27
| |
27
| |
|
c-
Met
|
|
Positive
|
203
|
1.0 (Ref)
|
34
|
1.98 (0.79, 5.54)
|
47
|
2.63 (1.14, 6.70)
|
28
|
1.43 (0.61, 3.60)
|
16
|
0.58 (0.23, 1.44)
|
|
Negative
|
89
| |
7
| |
8
| |
9
| |
11
| |
|
Survivin
|
|
Positive
|
240
|
1.0 (Ref)
|
34
|
1.32 (0.50, 4.20)
|
56
|
7.54 (1.74, 61.08)
|
30
|
1.25 (0.05, 3.52)
|
23
|
1.41 (0.46, 4.91)
|
|
Negative
|
62
| |
6
| |
2
| |
7
| |
5
| |
- Results are odds ratio (OR) adjusted by age and 95% confidence interval.
- EGFR: epidermal growth factor receptor, PTEN: phosphatase and tensin homolog deleted on chromosome 10, Bcl-2: B-cell lymphoma 2, c-Met: hepatocyte growth factor receptor.
